Lupin has signed an exclusive licensing agreement with Neopharmed for its gastroenterology brand Plasil® in the Philippines and Brazil. Lupin’s subsidiaries, Multicare Pharmaceuticals in the Philippines and MedQuimica in Brazil, will market and promote Plasil®. Neopharmed will manage product supply in the Philippines, and production for Brazil will shift to MedQuimica’s facility. This partnership expands Lupin’s presence in emerging markets and enhances its gastroenterology portfolio.
Partnership with Neopharmed
Lupin Limited (Lupin) has entered into an exclusive licensing agreement with Neopharmed Gentili S.p.A for the Gastroenterology brand Plasil® in the Philippines and Brazil, effective December 18, 2025. This agreement aims to leverage Neopharmed’s expertise in the region and strengthen Lupin’s market presence.
Agreement Details
Under the terms of the agreement, Lupin’s subsidiaries, Multicare Pharmaceuticals in the Philippines, and MedQuimica in Brazil, will hold the marketing and promotional rights for Plasil® in their respective markets. Neopharmed will oversee product supply in the Philippines, ensuring adherence to quality standards. For Brazil, production will be localized to MedQuimica’s manufacturing facility.
Strategic Impact
This collaboration will enhance Lupin’s gastroenterology portfolio and expand its reach in key emerging markets. The partnership allows Lupin to leverage its local presence, regulatory expertise, and commercial capabilities in the Philippines and Brazil. This will improve patient access to Plasil®.
Statements
Fabrice Egros, President of Corporate Development, Lupin, stated that the partnership with Neopharmed marks a significant milestone in expanding access to Plasil® and delivering meaningful health outcomes.
Matteo Meazzini, Director of Business Development, Neopharmed Gentili, highlighted the agreement as a commitment to expanding Neopharmed’s international footprint and ensuring Plasil® is available to every patient in need.
Source: BSE
